RxDoctor Payments Data

Sunil Kadakia, MD

Interventional Cardiology · Fox River Grove, ILNPI 1780763516

Payments from drug & device makers

$4,548in general payments, 2019–2025

Across 194 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$613
  • Abiomed$556
  • Boehringer Ingelheim$376
  • Novo Nordisk$339
  • Esperion Therapeutics, Inc.$290
  • Johnson & Johnson$236
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$44510%
  • Food & beverage$3,96887%
  • Education$1343%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,548 in reported general payments places this provider in the 30th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$339,315
Medicare patients
541
Services billed
2,872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban240$333,089
EntrestoSacubitril/Valsartan72$119,578
JardianceEmpagliflozin77$116,220
XareltoRivaroxaban49$63,355
MounjaroTirzepatide16$18,254
WegovySemaglutide11$15,183
Metoprolol Succinate1,008$13,426
FarxigaDapagliflozin Propanediol13$13,054
EdarbiAzilsartan Medoxomil13$8,860
Atorvastatin Calcium744$6,757
Ranolazine ErRanolazine51$4,648
Losartan Potassium485$4,517
ClopidogrelClopidogrel Bisulfate233$3,110
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide93$2,793
Rosuvastatin Calcium237$2,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$173$333,089240 claims
NovartisEntresto$613$119,57872 claims
Boehringer IngelheimJardiance$376$116,22077 claims
Johnson & JohnsonXarelto$236$63,35549 claims
Novo NordiskWegovy$339$15,18311 claims
AstraZenecaFarxiga$203$13,05413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Fox River Grove

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →